Physician profile
John G Barnes
NPI 1033160114
$3,817.96
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2020: $579 · 2021: $719 · 2022: $776 · 2023: $589 · 2024: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $991.50 | 2021-2024 | Ubrelvy, Vraylar, Synthroid |
| Amgen INC. | $573.45 | 2019-2024 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $323.12 | 2019-2023 | Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $207.92 | 2019-2022 | |
| Glaxosmithkline, LLC. | $199.59 | 2019-2023 | Shingrix, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.90 | 2019-2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.08 | 2019-2022 | |
| Pfizer INC. | $109.46 | 2019-2023 | |
| Astellas Pharma US INC | $108.37 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $106.62 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $100.85 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $90.89 | 2019-2024 | Breztri |
| Amarin Pharma, INC. | $80.26 | 2020 | |
| Boston Scientific Corporation | $62.62 | 2019-2024 | Watchman Flx |
| Lilly USA, LLC | $62.17 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $54.26 | 2020 | |
| Medtronic Vascular, INC. | $43.90 | 2019 | |
| Inspire Medical Systems, INC. | $41.78 | 2023-2024 | Inspire |
| Teva Pharmaceuticals USA, INC. | $40.20 | 2019-2022 | |
| Nalpropion Pharmaceuticals LLC | $37.45 | 2019 | |
| Genentech USA, INC. | $37.13 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $31.35 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $27.05 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $25.64 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $24.26 | 2019-2020 | |
| Impulse Dynamics (USA) INC. | $21.15 | 2023 | Optimizer |
| Biohaven Pharmaceutical Holding Company LTD. | $19.47 | 2022 | |
| Ardelyx, INC. | $17.40 | 2023 | Ibsrela |
| Corium, LLC | $16.90 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $16.22 | 2024 | Opsumit, Uptravi |
| Endo Pharmaceuticals INC. | $15.42 | 2019 | |
| Currax Pharmaceuticals LLC | $14.86 | 2021 | |
| Abbott Laboratories | $14.68 | 2021 | |
| Ironshore Pharmaceuticals INC. | $12.46 | 2019 | |
| Amneal Pharmaceuticals LLC | $12.35 | 2022 | |
| Shire North American Group INC | $11.74 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.